COPREXA Trademark

Trademark Overview


On Wednesday, August 15, 2007, a trademark application was filed for COPREXA with the United States Patent and Trademark Office. The USPTO has given the COPREXA trademark a serial number of 77256020. The federal status of this trademark filing is ABANDONED - EXPRESS as of Tuesday, July 1, 2008. This trademark is owned by Pipex Pharmaceuticals, Inc.. The COPREXA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, oral, small-molecule, anti-copper agent that is highly specific for lowering the levels of free copper in serum; reducing toxic free copper levels and substantially improve clinical outcomes in neurologically-presenting Wilson's disease patients; treatment for fibrotic disorders, including idiopathic pulmonary fibrosis, based upon the rationale that the fibrotic disease process is dependent upon the availability of endogenous free copper; possible treatment for primary biliary cirrhosis, an autoimmune and fibrotic disease which targets the bile ducts of the liver; and treatment of other central nervous system diseases in which abnormal serum and CNS copper homeostasis are implicated, such as Alzheimer's disease
coprexa

General Information


Serial Number77256020
Word MarkCOPREXA
Filing DateWednesday, August 15, 2007
Status601 - ABANDONED - EXPRESS
Status DateTuesday, July 1, 2008
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesPharmaceutical preparations, namely, oral, small-molecule, anti-copper agent that is highly specific for lowering the levels of free copper in serum; reducing toxic free copper levels and substantially improve clinical outcomes in neurologically-presenting Wilson's disease patients; treatment for fibrotic disorders, including idiopathic pulmonary fibrosis, based upon the rationale that the fibrotic disease process is dependent upon the availability of endogenous free copper; possible treatment for primary biliary cirrhosis, an autoimmune and fibrotic disease which targets the bile ducts of the liver; and treatment of other central nervous system diseases in which abnormal serum and CNS copper homeostasis are implicated, such as Alzheimer's disease

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, August 20, 2007
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NamePipex Pharmaceuticals, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressAnn Arbor, MI 48108

Trademark Events


Event DateEvent Description
Tuesday, July 1, 2008ABANDONMENT NOTICE MAILED - EXPRESS ABANDONMENT
Tuesday, July 1, 2008ABANDONMENT - EXPRESS MAILED
Monday, June 30, 2008TEAS EXPRESS ABANDONMENT RECEIVED
Thursday, June 26, 2008EXAMINER'S AMENDMENT ENTERED
Thursday, June 26, 2008NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Thursday, June 26, 2008EXAMINERS AMENDMENT E-MAILED
Thursday, June 26, 2008EXAMINERS AMENDMENT -WRITTEN
Monday, November 26, 2007NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, November 26, 2007NON-FINAL ACTION E-MAILED
Monday, November 26, 2007NON-FINAL ACTION WRITTEN
Friday, November 23, 2007ASSIGNED TO EXAMINER
Monday, August 20, 2007NEW APPLICATION ENTERED IN TRAM